Related Experiment Videos
Augmented systemic immunity in mice implanted with tumor necrosis factor-alpha gene-transduced Meth-A-cells
1Department of Internal Medicine (Section 4), Sapporo Medical University, School of Medicine.
Japanese Journal of Cancer Research : Gann
|March 1, 1994
Summary
Gene-modified tumor cells producing tumor necrosis factor (TNF) enhanced systemic immunity, leading to reduced tumor growth and increased survival in mice. This suggests TNF-gene-modified tumor cells show promise as cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- Methylcholanthrene-induced fibrosarcoma (Meth-A) is a common tumor model.
- Tumor necrosis factor (TNF) plays a crucial role in immune responses and tumor rejection.
- Gene modification of tumor cells is a potential strategy for cancer immunotherapy.
Purpose of the Study:
- To investigate the mechanism of reduced tumorigenicity in TNF-producing Meth-A tumor cells.
- To compare systemic immune responses between mice bearing TNF-producing and non-producing Meth-A cells.
- To evaluate the potential of TNF gene-modified tumor cells as cancer vaccines.
Main Methods:
- Syngeneic BALB/c mice were inoculated with either unmodified Meth-A cells (M0) or Meth-A cells engineered to produce TNF (C5).
- Systemic immune responses, including lymphokine-activated killer (LAK) cell activity, cytotoxic T lymphocyte (CTL) activity, T cell populations, and MHC class I expression, were compared between the two groups.
- Tumor regression and animal survival were monitored.
Main Results:
- Mice bearing TNF-producing Meth-A cells (C5) exhibited longer lifespans and tumor regression compared to mice with unmodified Meth-A cells (M0).
- Spleen cells from C5-bearing mice induced higher LAK and CTL activity against both M0 and C5 tumor cells.
- C5 tumor cells were more sensitive to LAK-induced cytotoxicity than M0 cells.
- Increased populations of Lyt2 (CD8)-positive T cells and higher expression of MHC class I antigen were observed on C5 cells.
- These findings indicate augmented host systemic immunity and increased tumor cell immunogenicity in mice bearing TNF-gene-modified tumor cells.
Conclusions:
- Augmented host systemic immunity, driven by increased tumor cell immunogenicity, is a key mechanism behind the reduced tumorigenicity of TNF-producing Meth-A cells.
- TNF gene-modified tumor cells can enhance anti-tumor immune responses, leading to tumor regression and improved survival.
- The use of TNF gene-modified tumor cells holds promise as a potential vaccine strategy for therapeutic and prophylactic cancer applications.